Orpha Labs   Report issue

For profit Phase 2
Founded: New York NY United States (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2014
NCT03354533
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Orpha Labs

Active Ingredients

Drugs in Phase 2 Trials (3)

d-mannose (2 trials)

fucose (1 trial)

orl-1b (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Biotinidase Deficiency (Phase 2)

Glycogen Storage Disease (Phase 2)

Metabolic Diseases (Phase 2)

Tissue Adhesions (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3